Mugiya T, Mothibe M, Khathi A, Ngubane P, Sibiya N
Front Pharmacol. 2024; 15:1355171.
PMID: 38362147
PMC: 10867135.
DOI: 10.3389/fphar.2024.1355171.
Kumar S A, Patel S, Patel S, Parikh P
J Diabetes Metab Disord. 2023; 22(1):61-71.
PMID: 37255821
PMC: 10225458.
DOI: 10.1007/s40200-022-01164-3.
Althubiti M
Saudi J Med Med Sci. 2022; 10(3):183-191.
PMID: 36247049
PMC: 9555044.
DOI: 10.4103/sjmms.sjmms_492_21.
Ma J, Sui F, Liu Y, Yuan M, Dang H, Liu R
Endocrine. 2022; 78(3):446-457.
PMID: 36205915
DOI: 10.1007/s12020-022-03202-9.
Welsh N
Ups J Med Sci. 2022; 127.
PMID: 36187072
PMC: 9487420.
DOI: 10.48101/ujms.v127.8841.
Antidiabetic Effects of the Senolytic Agent Dasatinib.
Salaami O, Kuo C, Drake M, Kuchel G, Kirkland J, Pignolo R
Mayo Clin Proc. 2021; 96(12):3021-3029.
PMID: 34772496
PMC: 8648964.
DOI: 10.1016/j.mayocp.2021.06.025.
Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.
Lundholm M, Charnogursky G
Clin Case Rep. 2020; 8(7):1238-1240.
PMID: 32695366
PMC: 7364065.
DOI: 10.1002/ccr3.2901.
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.
Yu L, Liu J, Huang X, Jiang Q
Sci Rep. 2019; 9(1):17601.
PMID: 31772301
PMC: 6879732.
DOI: 10.1038/s41598-019-54033-0.
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?.
Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogne J
TH Open. 2019; 2(1):e68-e88.
PMID: 31249931
PMC: 6524858.
DOI: 10.1055/s-0038-1624566.
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
Okada N, Niimura T, Zamami Y, Hamano H, Ishida S, Goda M
Cancer Med. 2018; 8(1):174-181.
PMID: 30561126
PMC: 6346261.
DOI: 10.1002/cam4.1920.
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Gomez-Samano M, Baquerizo-Burgos J, Coronel M, Wong-Campoverde B, Villanueva-Martinez F, Molina-Botello D
BMC Endocr Disord. 2018; 18(1):77.
PMID: 30390651
PMC: 6215634.
DOI: 10.1186/s12902-018-0303-x.
Redox-Dependent Inflammation in Islet Transplantation Rejection.
Barra J, Tse H
Front Endocrinol (Lausanne). 2018; 9:175.
PMID: 29740396
PMC: 5924790.
DOI: 10.3389/fendo.2018.00175.
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Duggan B, Foley K, Henriksbo B, Cavallari J, Tamrakar A, Schertzer J
Sci Rep. 2017; 7(1):1578.
PMID: 28484277
PMC: 5431485.
DOI: 10.1038/s41598-017-01822-0.
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
Steegmann J, Baccarani M, Breccia M, Casado L, Garcia-Gutierrez V, Hochhaus A
Leukemia. 2016; 30(8):1648-71.
PMID: 27121688
PMC: 4991363.
DOI: 10.1038/leu.2016.104.
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?.
Iurlo A, Orsi E, Cattaneo D, Resi V, Bucelli C, Orofino N
Oncotarget. 2015; 6(32):33944-51.
PMID: 26376678
PMC: 4741815.
DOI: 10.18632/oncotarget.5580.
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Ozanne J, Prescott A, Clark K
Biochem J. 2014; 465(2):271-9.
PMID: 25351958
PMC: 4286194.
DOI: 10.1042/BJ20141165.
Clinical review: kinase inhibitors: adverse effects related to the endocrine system.
Lodish M
J Clin Endocrinol Metab. 2013; 98(4):1333-42.
PMID: 23450053
PMC: 3615204.
DOI: 10.1210/jc.2012-4085.
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.
Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T
Int J Hematol. 2012; 97(1):135-8.
PMID: 23179903
DOI: 10.1007/s12185-012-1222-7.
Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation.
Holzer R, Park E, Li N, Tran H, Chen M, Choi C
Cell. 2011; 147(1):173-84.
PMID: 21962514
PMC: 3295636.
DOI: 10.1016/j.cell.2011.08.034.
Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.
Mokhtari D, Li T, Lu T, Welsh N
PLoS One. 2011; 6(9):e24831.
PMID: 21935477
PMC: 3173488.
DOI: 10.1371/journal.pone.0024831.
